A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma

BACKGROUND: Molecular targeted therapies were found to be efficacious and safer in the treatment of metastatic renal cell carcinoma (mRCC). Sorafenib is the first target agent (TA) to report a benefit in this disease and has largely established a prominent role in progression-free survival (PFS). Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hai-Tao, Xia, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344165/
https://www.ncbi.nlm.nih.gov/pubmed/30608388
http://dx.doi.org/10.1097/MD.0000000000013779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344165/
https://www.ncbi.nlm.nih.gov/pubmed/30608388
http://dx.doi.org/10.1097/MD.0000000000013779

Ejemplares similares